Brief: EMA Gets Application For Marketing Authorisation For Regkirona For Treating COVID-19
04/10/2021 13:00
Oct 4 (Reuters) - European Medicines Agency:
* EMA RECEIVES APPLICATION FOR MARKETING AUTHORISATION FOR
REGKIRONA (REGDANVIMAB) FOR TREATING PATIENTS WITH COVID-19
* EMA SAYS WILL ASSESS THE BENEFITS AND RISKS OF REGKIRONA
UNDER A
REDUCED TIMELINE AND COULD ISSUE AN OPINION WITHIN TWO MONTHS
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won